Trials / Completed
CompletedNCT02834611
Ceramide NanoLiposome in Patients With Advanced Solid Tumors
Phase I Study of C6 Ceramide NanoLiposome in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Keystone Nano, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a dose escalation study of Ceramide NanoLiposome in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ceramide NanoLiposome | Intravenous administration of Ceramide NanoLiposome |
Timeline
- Start date
- 2017-03-15
- Primary completion
- 2023-08-03
- Completion
- 2023-11-01
- First posted
- 2016-07-15
- Last updated
- 2024-05-29
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02834611. Inclusion in this directory is not an endorsement.